Discovery and Feasibility Study of Medical Fluorophore 33 as a Novel Theranostic Agent

Fluorescent dyes have garnered significant attention as theranostic platforms owing to their inherent characteristics. In this study, we present the discovery of Medical Fluorophore 33 (MF33), a novel and potent theranostic agent with a phenaleno-isoquinolinium salt structure that can serve as a Cancer therapeutic strategy. The synthesis of MF33 is readily achievable through a simple Rh(III)-catalyzed reaction. Moreover, MF33 displayed strong fluorescence signals, excellent microsomal stability, and high biocompatibility in vivo. It induces significant Apoptosis in Cancer cells via the p53/p21/Caspase-3 signaling pathway, leading to selective cytotoxicity in various Cancer cells. In vivo fluorescence imaging with MF33 enabled the visualization of sentinel lymph nodes in living mice. Notably, repeated intraperitoneal administration of MF33 resulted in antitumor activity in mice with colorectal Cancer. Collectively, our findings suggest that phenaleno-isoquinolinium salt-based MF33 is a viable theranostic agent for biomedical imaging and Cancer treatment.

cancer therapy; fluorescent dye; medical fluorophore; phenaleno-isoquinolinium; sentinel lymph nodes; theranostic.